Table 3 Risk of cancer in biologic-naïve RA patients (including TNFi treated patients prior to TNFi exposure) compared with the general population, with relative risk in the TNFi treated patients compared to biologic naïve patients

Site

O

E

SIR (95 % CI)

RR (95 % CI) ^b

All invasive cancers

33

24.86

1.33 (0.94, 1.87)

0.70 (0.39, 1.25)

Melanoma

5

1.97

2.54 (1.06, 6.11)

0.68 (0.16, 2.87)

Lung

6

2.55

2.35 (1.06, 5.24)

0.26 (0.05, 1.27)

Lymphoid cancers^a

1

1.58

0.63 (0.09, 4.49)

4.03 (0.18, 89.28)

Colorectal

2

3.6

0.56 (0.14, 2.22)

0.19 (0.003, 13.94)

Prostate

5

3.61

1.39 (0.58, 3.33)

1.20 (0.33, 4.40)

Female breast

5

3.58

1.40 (0.58, 3.36)

0.20 (0.04, 1.06)